Amgen welcomes European Commission report on EU biosimilars uptake

Amgen welcomes European Commission report on EU biosimilars uptake 
MISSISSAUGA, ON, April 30, 2013 /CNW/ - Amgen, a biotechnology company 
developing both innovative biologic and biosimilar medicines, welcomes a new 
report from the European Commission detailing Europe's strong regulatory and 
commercial foundation for biosimilars in the healthcare marketplace. The 
report shows that biosimilars are helping improve competition and thus may be 
increasing access to biologic medicines for patients. 
The science-led regulatory framework in the European Union (EU) has 
established confidence in biosimilars which has allowed for these therapeutic 
alternatives to successfully enter into clinical practice. As governments, 
industry and the healthcare sector work together to improve health outcomes, 
the report reaffirms that protecting patient safety is the cornerstone of the 
EU's regulatory framework for biosimilar medicines. 
Amgen, a core stakeholder in the consultation process for this report, 
welcomes the opportunity this consensus document provides for ongoing balanced 
and informed discussions on the European biosimilars experience. This report 
is designed to help national governments, health care professionals and 
patients make informed choices on the role current and future biosimilar 
medicines may have in achieving optimal healthcare outcomes. 
For more information or to set up an interview, please contact: 
Natasha Bond Amgen Canada Tel: 905-285-3007 
SOURCE: Amgen Canada 
To view this news release in HTML formatting, please use the following URL: 
CO: Amgen Canada
ST: Ontario
-0- Apr/30/2013 12:30 GMT
Press spacebar to pause and continue. Press esc to stop.